{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:36:33Z","timestamp":1762364193663,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.urolonc.2025.02.003","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T07:27:59Z","timestamp":1739863679000},"page":"441.e1-441.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of IRAES on the outcomes of pembrolizumab therapy in patients with MUC: A comprehensive analysis of severity and the type and number of affected organs"],"prefix":"10.1016","volume":"43","author":[{"given":"Ichiro","family":"Yonese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Toide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Soma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Yoneoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Oguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Numao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Yonese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.02.003_bib0001","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0002","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with Immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0004","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/19490976.2018.1527167","article-title":"The intimate relationship between gut microbiota and cancer immunotherapy","volume":"10","author":"Elkrief","year":"2019","journal-title":"Gut Microbes"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0005","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0006","doi-asserted-by":"crossref","first-page":"e0216954","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"Plos One"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0007","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12094-020-02397-5","article-title":"Anti-PD-1\/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis","volume":"23","author":"Park","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0008","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1186\/s12885-020-07142-3","article-title":"Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody","volume":"20","author":"Matsuoka","year":"2020","journal-title":"Bmc Cancer"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0009","doi-asserted-by":"crossref","first-page":"327","DOI":"10.21873\/cdp.10219","article-title":"Prognostic significance of immune-related adverse events in metastatic renal cell carcinoma patients treated with immune-checkpoint-inhibitors","volume":"3","author":"Yasuda","year":"2023","journal-title":"Cancer Diagn Progn"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.clgc.2020.07.003","article-title":"Association between the occurrence and spectrum of immune-related adverse events and efficacy of Pembrolizumab in Asian patients with advanced urothelial cancer: multicenter retrospective analyses and systematic literature review","volume":"19","author":"Kijima","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0011","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1111\/cas.15539","article-title":"Immune-related adverse events in urothelial cancer patients: adjustment for immortal time bias","volume":"113","author":"Otsuka","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0012","doi-asserted-by":"crossref","first-page":"e003965","DOI":"10.1136\/jitc-2021-003965","article-title":"Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis","volume":"10","author":"Kawai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0013","doi-asserted-by":"crossref","first-page":"e000371","DOI":"10.1136\/jitc-2019-000371","article-title":"Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors","volume":"8","author":"Nuzzo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0014","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0015","doi-asserted-by":"crossref","first-page":"1032221","DOI":"10.3389\/fimmu.2022.1032221","article-title":"Immunogenomic correlates of immune-related adverse events for anti-programmed cell death 1 therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0016","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ccell.2020.05.002","article-title":"Visualizing synaptic transfer of tumor antigens among dendritic cells","volume":"37","author":"Ruhland","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0017","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0018","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0019","doi-asserted-by":"crossref","first-page":"703893","DOI":"10.3389\/fonc.2021.703893","article-title":"Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer","volume":"11","author":"Daniello","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0020","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0021","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0022","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab Vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0023","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2018.05.002","article-title":"Tumor exosomes block dendritic cells maturation to decrease the T cell immune response","volume":"199","author":"Ning","year":"2018","journal-title":"Immunol Lett"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0024","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.urolonc.2025.02.003_bib0025","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2567.2010.03255.x","article-title":"T-cell exhaustion: characteristics, causes and conversion","volume":"129","author":"Yi","year":"2010","journal-title":"Immunology"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:32:00Z","timestamp":1762363920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925000286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1078143925000286"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.003","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of IRAES on the outcomes of pembrolizumab therapy in patients with MUC: A comprehensive analysis of severity and the type and number of affected organs","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}